BSE Live
Dec 03, 16:00Prev. Close
20.15
Open Price
20.15
Bid Price (Qty.)
19.15 (30)
Offer Price (Qty.)
20.15 (36)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Cash Flow of Elder Projects (in Rs. Cr.) | Mar 08 | Mar 07 | Mar 06 | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | -0.92 | -1.57 | 2.35 | 0.46 | 1.64 | |
| Net CashFlow From Operating Activities | -11.81 | -9.14 | -0.27 | 0.85 | 4.51 | |
| Net Cash Used In Investing Activities | -0.04 | -1.98 | 0.67 | 0.13 | -0.61 | |
| Net Cash Used From Financing Activities | 13.99 | 11.18 | -0.33 | -1.07 | 3.88 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 2.15 | 0.05 | 0.07 | -0.09 | -0.02 | |
| Cash And Cash Equivalents Begin of Year | 0.28 | 0.23 | 0.16 | 0.25 | 0.27 | |
| Cash And Cash Equivalents End Of Year | 2.43 | 0.28 | 0.23 | 0.16 | 0.25 |
13.04.2026
10.04.2026
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth